Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A.
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
J Natl Compr Canc Netw. 2015; 13(12):1501-1508
Doi: 10.6004/jnccn.2015.0178
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Prochazka Katharina
- Co-Autor*innen der Med Uni Graz
- Deutsch Alexander
- Neumeister Peter
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Several serum parameters have been evaluated for adding prognostic value to clinical scoring systems in diffuse large B-cell lymphoma (DLBCL), but none of the reports used multivariate testing of more than one parameter at a time. The goal of this study was to validate widely available serum parameters for their independent prognostic impact in the era of the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) score to determine which were the most useful. This retrospective bicenter analysis includes 515 unselected patients with DLBCL who were treated with rituximab and anthracycline-based chemoimmunotherapy between 2004 and January 2014. Anemia, high C-reactive protein, and high bilirubin levels had an independent prognostic value for survival in multivariate analyses in addition to the NCCN-IPI, whereas neutrophil-to-lymphocyte ratio, high gamma-glutamyl transferase levels, and platelets-to-lymphocyte ratio did not. In our cohort, we describe the most promising markers to improve the NCCN-IPI. Anemia and high C-reactive protein levels retain their power in multivariate testing even in the era of the NCCN-IPI. The negative role of high bilirubin levels may be associated as a marker of liver function. Further studies are warranted to incorporate these markers into prognostic models and define their role opposite novel molecular markers. Copyright © 2015 by the National Comprehensive Cancer Network.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Anthracyclines - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biomarkers - blood
- Female -
- Follow-Up Studies -
- Humans -
- Inflammation Mediators - metabolism
- Liver - metabolism
- Lymphoma, Large B-Cell, Diffuse - blood
- Lymphoma, Large B-Cell, Diffuse - drug therapy
- Lymphoma, Large B-Cell, Diffuse - mortality
- Lymphoma, Large B-Cell, Diffuse - pathology
- Male -
- Middle Aged -
- Neoplasm Staging -
- Prognosis -
- Retrospective Studies -
- Rituximab - administration & dosage
- Survival Analysis -
- Treatment Outcome -
- Young Adult -